全日程公布！多维技术创新与类器官研究新范式研讨会1月21日召开

Core Insights - Organoid technology is a revolutionary model in life sciences, showing great potential in simulating human organ development, disease mechanism research, and drug development, but faces significant bottlenecks in scaling and standardization [1] - Current organoid research needs to move beyond traditional morphological observations to deeper functional analyses, particularly in assessing cellular energy metabolism, which is crucial for evaluating organoid viability, drug toxicity, and metabolic disease phenotypes [1] - The reliance on manual operations and animal-derived matrix gels in organoid culture leads to significant sample variability and high costs, hindering high-throughput drug screening applications [1] Group 1 - A single technical pathway is insufficient to address systemic issues in organoid research; a cross-platform, multidimensional technical collaboration is necessary to create an integrated solution from model establishment to standardized culture and deep functional characterization [2] - Agilent, in collaboration with Instrument Information Network, will host a webinar on January 21, 2026, titled "Multidimensional Technological Innovation and New Paradigms in Organoid Research," inviting leading scholars and technical experts to discuss pathways for standardized organoid research [2] Group 2 - The agenda for the webinar includes presentations from distinguished guests, such as: - "Construction of Functional Organs Based on Organoid Assembly and Precision Medicine Research" by Dr. Pang Yuan from Tsinghua University [6] - "Instantaneous Dynamics of Organoid Metabolism: Standardized Application of Seahorse XF in 3D Models" by Wei Yufeng from Agilent Technologies (China) [7] - "Multi-modal Automation Platform Compatible with Phenotype and Viability Analysis to Assist in Standardized Organoid Model Establishment" by Yang Jingzhe from Agilent Technologies (China) [7] - "Construction and Application of Engineered Multi-organ Chips: From Absorption Metabolism to Tumor Immune Regulation" by Liu Dongdong from the Chinese Academy of Sciences [7]